Compare FINV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | CSTL |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | FINV | CSTL |
|---|---|---|
| Price | $5.02 | $39.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.55 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 1.0M | 351.9K |
| Earning Date | 11-19-2025 | 02-26-2026 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $1,969,555,571.00 | $343,530,000.00 |
| Revenue This Year | $6.02 | $1.69 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | 8.81 | ★ 10.15 |
| 52 Week Low | $4.70 | $14.59 |
| 52 Week High | $11.08 | $42.18 |
| Indicator | FINV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 53.75 |
| Support Level | $5.17 | $37.29 |
| Resistance Level | $5.49 | $41.35 |
| Average True Range (ATR) | 0.21 | 1.36 |
| MACD | 0.00 | -0.26 |
| Stochastic Oscillator | 0.00 | 38.49 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.